Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Hi-Tech Pharmacal

This article was originally published in The Tan Sheet

Executive Summary

Hi-Tech Pharmacal: Acquires licensing rights to a dietary supplement called Huperzine and its analogs in the U.S., Canada and Europe from the Mayo Clinic in Rochester, Minn. Hi-Tech is planning to conduct clinical trials in the U.S. on Huperzine, a Chinese folk remedy that has been shown to inhibit the enzyme responsible for the breakdown of acetylcholine, a neurotransmitter believed to be important in learning and memory. The natural compound is derived from the club moss Huperzine serrata. "Results suggest" that Huperzine "improves learning and memory in certain patients. However, these suggested results have not been substantiated by clinical trials," Amityville, N.Y.-based Hi-Tech says...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel